FMP

FMP

Enter

CLDX - Celldex Therapeutics...

Financial Summary of Celldex Therapeutics, Inc.(CLDX), Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclona

photo-url-https://financialmodelingprep.com/image-stock/CLDX.png

Celldex Therapeutics, Inc.

CLDX

NASDAQ

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

36.32 USD

-1.78 (-4.9%)

About

ceo

Mr. Anthony S. Marucci M.B.A.

sector

Healthcare

industry

Biotechnology

website

https://www.celldex.com

exchange

NASDAQ

Description

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, wh...

CIK

0000744218

ISIN

US15117B2025

CUSIP

15117B202

Address

Perryville III Building

Phone

908 200 7500

Country

US

Employee

160

IPO Date

May 15, 1986

Summary

CIK

0000744218

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

15117B202

ISIN

US15117B2025

Country

US

Price

36.32

Beta

1.6

Volume Avg.

905.75k

Market Cap

2.39B

Shares

-

52-Week

22.11-53.18

DCF

-4.65

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-12.7

P/B

-

Website

https://www.celldex.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest CLDX News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep